August 6, 2008
Tolerx’s Partner Genentech Initiates Phase I Monoclonal Antibody Trial
Tolerx has announced that Genentech, a collaborator, has moved a modified version of TRX1, MTRX1011A, an anti-CD4 monoclonal antibody, into a Phase I clinical trial that has begun enrolling patients.
The clinical trial is evaluating the safety and tolerability of both single and multiple doses of MTRX1011A. The initiation of the Phase I clinical trial resulted in the realization of an additional milestone by Tolerx.
Douglas Ringler, president and CEO of Tolerx, said: "We are extremely pleased that our collaboration with Genentech has resulted in the continued advancement of the program, and we look forward to continued progress."